Clinical significance of anti-nucleocapsid-IgG sero-positivity in SARS-CoV-2 infection in hospitalized patients in North Dakota  

作　　者：Bakir Dzananovic Mark Williamson Casmiar Nwaigwe Chittaranjan Routray 

机构地区：[1]Department of Medicine,Idaho College of Osteopathic Medicine,Meridian,ID 83642,United States [2]Department of Biostatistics,Epidemiology and Research Design Core,University of North Dakota,Grand Forks,ND 58202,United States [3]Department of Internal Medicine,University of North Dakota School of Medicine and Health Sciences,Minot,ND 58701,United States [4]Family Medicine,University of North Dakota School of Medicine and Health Sciences,Minot,ND 58701,United States [5]Department of Internal Medicine,Trinity Health,Minot,ND 58701,United States

出　　处：《World Journal of Clinical Infectious Diseases》2022年第2期50-60,共11页世界临床传染病学杂志

基　　金：the National Institute of General Medical Sciences of the National Institutes of Health under Award,No.U54GM128729.

摘　　要：BACKGROUND During the peak of the coronavirus diseases 2019(COVID-19)pandemic,clinicians actively studied the utility of various epidemiologic-clinical parameters to determine the prognosis for patients hospitalized with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.Serum IgG antibody level,DDimer,C-reactive protein and neutrophil to lymphocyte ratio,etc.were studied to assess their association with the clinical course in hospitalized patients and predict who may be at increased risk for poor clinical outcome.However,the influence of SARS-CoV-2-anti-nucleocapsid-IgG antibody(IgG-N)sero-positivity on the clinical outcome of patients with COVID-19 is largely unknown.AIM To study the influence of SARS-CoV-2 anti-nucleocapsid-IgG seropositivity on clinical course and diseases severity in hospitalized COVID-19 patients.METHODS We conducted a retrospective study of adults admitted to a tertiary care community hospital in North Dakota with COVID-19.Included patients had severeCOVID-19 disease or worse and so required supplemental oxygen on admission.They were serologically tested for SARS-CoV-2-anti-nuceocapsid-IgG(IgG-N).The IgG-N positive group were 26 patients and the IgG-N negative group had 33 patients.The groups received similar treatment for COVID-19 as approved by our healthcare system from Day 1 of admission until discharge or death.Measurable parameters for monitoring the patients’clinical course included the following:Length of hospitalization(LOS),use of high flow nasal canula(HFNC),use of noninvasive bilevel positive pressure ventilation(BiPAP),admission into the intensive care unit,need for mechanical ventilation(VENT);and the patient outcome/discharge or death.Other variables included were age,gender and body-mass-index,and duration of symptoms before presentation.For each variable,the outcome was modeled as a function of SARS-CoV-2-IgG-N status(positive or negative)using a generalized linear model.For LOS-days,a negative binomial distribution was used as it had a better fit than

关 键 词：COVID-19 SARS-CoV-2 IgG-N Anti-nucleocapsid IgG CYTOKINES 

分 类 号：R73[医药卫生—肿瘤]